Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Revenue for 8 consecutive years, with $6.3 million as the latest value for Q1 2026.

  • Quarterly Revenue fell 66.12% to $6.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $29.1 million through Feb 2026, down 53.83% year-over-year, with the annual reading at $84.0 million for FY2025, 53.95% up from the prior year.
  • Revenue for Q1 2026 was $6.3 million at Nurix Therapeutics, down from $7.9 million in the prior quarter.
  • The five-year high for Revenue was $30.7 million in Q2 2023, with the low at $6.3 million in Q1 2026.
  • Average Revenue over 5 years is $14.0 million, with a median of $12.6 million recorded in 2023.
  • The sharpest move saw Revenue skyrocketed 168.33% in 2023, then tumbled 66.12% in 2026.
  • Over 5 years, Revenue stood at $6.8 million in 2022, then soared by 123.49% to $15.2 million in 2023, then surged by 31.93% to $20.0 million in 2024, then crashed by 60.53% to $7.9 million in 2025, then fell by 20.8% to $6.3 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $6.3 million, $7.9 million, and $15.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.